Peter Thompson Sells 69,500 Shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Stock

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Director Peter Thompson sold 69,500 shares of the stock in a transaction dated Friday, August 23rd. The stock was sold at an average price of $13.03, for a total value of $905,585.00. Following the completion of the sale, the director now owns 83,695 shares of the company’s stock, valued at $1,090,545.85. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

ARS Pharmaceuticals Price Performance

SPRY stock traded up $0.24 during midday trading on Monday, hitting $13.20. The company’s stock had a trading volume of 876,687 shares, compared to its average volume of 715,928. The company’s fifty day moving average price is $10.43 and its 200 day moving average price is $9.36. ARS Pharmaceuticals, Inc. has a twelve month low of $2.55 and a twelve month high of $16.50. The stock has a market capitalization of $1.28 billion, a P/E ratio of -24.92 and a beta of 0.87.

ARS Pharmaceuticals (NASDAQ:SPRY) last issued its quarterly earnings results on Tuesday, August 6th. The company reported ($0.13) EPS for the quarter, missing the consensus estimate of ($0.12) by ($0.01). The company had revenue of $0.50 million during the quarter, compared to analysts’ expectations of $2.00 million. Equities analysts expect that ARS Pharmaceuticals, Inc. will post -0.66 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

SPRY has been the topic of several research reports. Leerink Partners boosted their price objective on shares of ARS Pharmaceuticals from $19.00 to $20.00 and gave the company an “outperform” rating in a research report on Monday, August 12th. Cantor Fitzgerald started coverage on ARS Pharmaceuticals in a report on Tuesday, August 20th. They issued an “overweight” rating and a $30.00 price target on the stock. Finally, Raymond James upgraded ARS Pharmaceuticals from an “outperform” rating to a “strong-buy” rating and increased their price objective for the stock from $18.00 to $22.00 in a report on Tuesday, August 13th. Five analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, ARS Pharmaceuticals presently has an average rating of “Buy” and an average price target of $22.75.

Institutional Trading of ARS Pharmaceuticals

Large investors have recently added to or reduced their stakes in the company. Vanguard Group Inc. lifted its position in shares of ARS Pharmaceuticals by 37.0% in the first quarter. Vanguard Group Inc. now owns 2,886,455 shares of the company’s stock valued at $29,500,000 after buying an additional 779,969 shares during the last quarter. ClariVest Asset Management LLC acquired a new stake in ARS Pharmaceuticals during the 1st quarter valued at $2,790,000. SG Americas Securities LLC boosted its position in ARS Pharmaceuticals by 861.5% during the second quarter. SG Americas Securities LLC now owns 111,592 shares of the company’s stock worth $950,000 after purchasing an additional 99,986 shares during the period. GSA Capital Partners LLP increased its holdings in shares of ARS Pharmaceuticals by 11.7% in the first quarter. GSA Capital Partners LLP now owns 128,889 shares of the company’s stock valued at $1,317,000 after purchasing an additional 13,545 shares during the last quarter. Finally, Franklin Resources Inc. raised its position in shares of ARS Pharmaceuticals by 5.9% in the fourth quarter. Franklin Resources Inc. now owns 4,098,497 shares of the company’s stock valued at $22,460,000 after purchasing an additional 229,988 shares during the period. Institutional investors and hedge funds own 68.16% of the company’s stock.

ARS Pharmaceuticals Company Profile

ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers.